This week, the overall grades of four medical devices stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Derma Sciences, Inc.’s (DSCI) rating falls this week to an F (“strong sell”), down from last week’s D (“sell”). Derma Sciences markets and sells a range of skin care, wound management, and specialty securement devices. In Portfolio Grader’s specific subcategories of Equity, Cash Flow and Sales Growth, DSCI also gets an F. Shares of the stock have been changing hands at an unusually rapid pace, three times the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of DSCI stock.
This week, St. Jude Medical, Inc. (STJ) falls to a D (“sell”), worse than last week’s grade of C (“hold”). St. Jude Medical makes and distributes cardiovascular medical devices. To get an in-depth look at STJ, get Portfolio Grader’s complete analysis of STJ stock.
Baxter International’s (BAX) rating weakens this week, dropping to a D versus last week’s C. Baxter International develops, manufactures and markets products related to hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The stock also gets an F in Earnings Revisions. For more information, get Portfolio Grader’s complete analysis of BAX stock.
This week, Zimmer Biomet Holdings, Inc.’s (ZBH) rating worsens to a D from the company’s C rating a week ago. The stock also rates an F in Earnings Momentum. Shares of the stock have been changing hands at an unusually rapid pace, twice the rate of the week prior. The stock currently has a trailing PE Ratio of 52.60. To get an in-depth look at ZBH, get Portfolio Grader’s complete analysis of ZBH stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
